Scpharmaceuticals Inc (SCPH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scpharmaceuticals Inc (SCPH) has a cash flow conversion efficiency ratio of 0.756x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.11 Million) by net assets ($-21.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SCPH stock market capitalisation for the company's overall valuation and market capitalisation.
Scpharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Scpharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Scpharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scpharmaceuticals Inc ranked by their cash flow conversion efficiency. See how well can Scpharmaceuticals Inc service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rimini Street Inc
NASDAQ:RMNI
|
-0.906x |
|
PETROTAL CORP.
F:SER1
|
0.036x |
|
Vitruvio Real Estate Socimi
MC:YVIT
|
0.008x |
|
Dongsung FineTec Co. Ltd
KQ:033500
|
-0.011x |
|
Jiangsu Bioperfectus Technologies Co Ltd
SHG:688399
|
0.007x |
|
Neuberger Berman IMF Inc
NYSE MKT:NBH
|
-0.035x |
|
Vysarn Ltd
AU:VYS
|
0.088x |
|
Value Line Inc
NASDAQ:VALU
|
0.049x |
Annual Cash Flow Conversion Efficiency for Scpharmaceuticals Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Scpharmaceuticals Inc from 2015 to 2024. View Scpharmaceuticals Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.32 Million | $-70.54 Million | -5.296x | -232.68% |
| 2023-12-31 | $37.22 Million | $-59.24 Million | -1.592x | -233.46% |
| 2022-12-31 | $72.43 Million | $-34.58 Million | -0.477x | +0.72% |
| 2021-12-31 | $56.47 Million | $-27.15 Million | -0.481x | -42.66% |
| 2020-12-31 | $82.17 Million | $-27.69 Million | -0.337x | +43.13% |
| 2019-12-31 | $51.37 Million | $-30.44 Million | -0.593x | -61.98% |
| 2018-12-31 | $78.74 Million | $-28.81 Million | -0.366x | -70.99% |
| 2017-12-31 | $106.00 Million | $-22.68 Million | -0.214x | -151.33% |
| 2016-12-31 | $-37.07 Million | $-15.46 Million | 0.417x | -21.12% |
| 2015-12-31 | $-18.24 Million | $-9.64 Million | 0.529x | -- |
About Scpharmaceuticals Inc
scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and … Read more